On this page
⚠ Educational content only Not medical or genetic advice. Speak with a healthcare provider or genetic counsellor before acting on anything here.
Autoinflammatory

Familial Mediterranean fever

FMF primarily affects individuals of Mediterranean and Middle Eastern descent, causing unpredictable attacks of pain and fever. These episodes are due to an overactive immune response and can significantly impact quality of life if not managed.

Autosomal recessive Autoinflammatory Tier B OMIM:249100
1:500-1,000 (Med)
Prevalence
Population estimate
25%
Inheritance
Autosomal recessive - if both parents are carriers, each child has a 25% chance of being affected; a carrier passes the variant on 50% of the time
1
Associated genes
MEFV

Available at Jeen Health

Clinical tests that include this

Overview

Familial Mediterranean fever (FMF) is a genetic disorder that falls under the category of autoinflammatory diseases. These conditions are marked by unprovoked episodes of inflammation, often without an obvious external trigger like infection. Individuals with FMF experience recurring attacks, typically lasting one to three days, which include fever alongside inflammation in the abdomen, chest, or joints [PMID:33678099].

FMF is most commonly observed in populations originating from the Mediterranean region, including Sephardic Jews, Armenians, Turks, and Arabs, where its prevalence is estimated to be between 1 in 500 and 1 in 1,000 people. While less common, FMF can also affect individuals from other ethnic backgrounds [PMID:33678099]. The unpredictable nature of these attacks can make daily life challenging for those affected.

Symptoms & clinical features

The hallmark symptoms of FMF are sudden, recurrent episodes of fever and inflammation. These attacks generally begin in childhood or adolescence, though onset can occur at any age. During an attack, individuals typically develop a high fever, often accompanied by severe pain in one or more areas.

Common manifestations include abdominal pain, which can be mistaken for appendicitis, and chest pain that may resemble pleurisy or pericarditis. Joint pain and swelling, often affecting large joints like the knees or ankles, are also frequently reported. Less common symptoms can include a characteristic skin rash, typically appearing on the lower legs, and muscle aches [PMID:34208034]. These attacks are typically self-limiting, resolving on their own within a few days, but the pain can be debilitating while they last.

Video: Genetics 101

Affected organs

FMF primarily affects serosal membranes, which are thin layers of tissue lining internal organs and cavities. This explains the common inflammation seen in the lining of the abdomen (peritonitis), the lungs (pleurisy), and around the heart (pericarditis). The joints, particularly large joints, are also frequently involved, leading to synovitis - inflammation of the joint lining.

Over time, if left unmanaged, chronic inflammation in FMF can lead to a serious complication known as amyloidosis. This condition occurs when an abnormal protein called amyloid builds up in organs, most commonly the kidneys, but also potentially the spleen, liver, and heart [PMID:34208034]. Amyloid deposits can impair organ function, leading to kidney failure in severe cases.

Multiple body systems
Multiple body systems
Systemic involvement
Cellular impact
Cellular impact
Mechanism at cellular level

Risks & severity

The severity of FMF can vary significantly among individuals, even within the same family. Some people experience frequent, intense attacks that severely impact their quality of life, while others have milder, less frequent episodes. The primary long-term risk associated with FMF is the development of amyloid A (AA) amyloidosis, which can lead to organ damage, especially kidney failure [PMID:34208034]. The risk of amyloidosis is significantly reduced with appropriate treatment.

Attacks typically begin in childhood, with about 90% of cases presenting before the age of 30. However, late-onset FMF can occur. The frequency of attacks can range from several times a month to just a few times a year. While the condition itself is not life-threatening, untreated amyloidosis can be. Early diagnosis and consistent management are crucial for preventing severe complications and improving long-term outcomes.

Genetic causes

Familial Mediterranean fever is caused by pathogenic changes in the *MEFV* gene. This gene provides instructions for making a protein called pyrin, also known as marenostrin. Pyrin is an important component of the innate immune system, which is the body's first line of defence against pathogens. It plays a key role in regulating inflammation by helping to control the production of inflammatory molecules.

Pathogenic variants in *MEFV* typically lead to a dysfunctional pyrin protein. When pyrin is not working correctly, it cannot effectively regulate inflammatory responses. This dysfunction results in an overactive inflammatory process, causing the unprovoked and recurrent attacks characteristic of FMF. More than 300 different pathogenic variants have been identified in the *MEFV* gene, with some being more common in certain ethnic groups [PMID:33678099].

  • MEFV
    MEFV innate immunity regulator, pyrin
    The MEFV gene provides instructions for producing the pyrin protein, which plays a crucial role in regulating the body's inflammatory response.

Inheritance pattern

Familial Mediterranean fever is inherited in an autosomal recessive pattern. This means that an individual must inherit two altered copies of the *MEFV* gene - one from each parent - to develop the condition. People who have only one altered copy of the *MEFV* gene are called carriers. Carriers typically do not show symptoms of FMF themselves, but they can pass the altered gene on to their children.

If both parents are carriers of a pathogenic *MEFV* variant, there is a 25% chance with each pregnancy that their child will inherit two altered copies and develop FMF. There is also a 50% chance their child will be a carrier, and a 25% chance their child will inherit two working copies of the gene and not be affected or a carrier.

♀ Carrier parent 1 altered copy ♂ Carrier parent 1 altered copy Affected Carrier Carrier Unaffected Affected Carrier Unaffected Circles = females · Squares = males

When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.

Diagnosis & testing

The diagnosis of FMF is typically made based on a combination of clinical symptoms, family history, and genetic testing. Clinicians use specific criteria, such as the Tel Hashomer criteria, to help identify characteristic features like recurrent fever, serositis (inflammation of serosal membranes), and a positive response to colchicine treatment.

Genetic testing for *MEFV* variants is available through the NHS Genomic Medicine Service and can confirm a suspected diagnosis. This testing is covered by NHS R-code R148 for individuals suspected of having FMF. A clinical geneticist or a rheumatologist may refer individuals for genetic testing, especially if there is a strong family history or if symptoms are typical of FMF. Genetic counselling is also offered to help families understand the implications of a diagnosis and the inheritance pattern.

Management & lifestyle

The primary aim of FMF management is to prevent inflammatory attacks and, crucially, to prevent the long-term complication of amyloidosis. The most effective treatment is typically a medication called colchicine, which is taken daily. Colchicine works by reducing the inflammatory response, significantly decreasing the frequency and severity of attacks in most individuals and, most importantly, preventing amyloid deposits from forming [PMID:34208034].

Regular follow-up with a specialist, such as a rheumatologist, is important to monitor the effectiveness of treatment and to check for any signs of complications, particularly kidney function, to detect amyloidosis early if it occurs. In cases where colchicine is not effective or not tolerated, other biologic therapies that target specific inflammatory pathways may be considered [PMID:33678099]. Adherence to medication and regular clinical reviews are key components of living well with FMF within the NHS care pathway.

UK care pathway

In the UK, individuals suspected of having an autoinflammatory condition like Familial Mediterranean fever can be referred by their GP to specialist services, often a rheumatologist or clinical geneticist. These specialists work within the NHS Genomic Medicine Service (GMS) framework. Genetic testing for FMF is available via the GMS, typically under R-code R148, which covers inherited disorders of immunity and inflammation.

If a genetic diagnosis of FMF is confirmed, patients are usually managed by a specialist team, often including rheumatologists and nephrologists if kidney involvement is present. Genetic counsellors are also available to provide information and support to individuals and families, helping them understand the genetic basis of the condition and its implications for family planning.

Frequently asked questions

What triggers an FMF attack?

FMF attacks are often unpredictable, but some individuals report that stress, strenuous exercise, infection, or even certain foods can be potential triggers. However, many attacks occur without any clear precipitating factor.

Is FMF contagious?

No, Familial Mediterranean fever is not contagious. It is a genetic condition caused by an inherited alteration in the *MEFV* gene, meaning it cannot be caught from another person.

Can FMF affect fertility or pregnancy?

Generally, FMF itself does not directly affect fertility. However, uncontrolled inflammation and particularly the development of amyloidosis can potentially have an impact. Most women with FMF can have successful pregnancies, especially if they continue their colchicine treatment under medical supervision.

How is FMF different from an autoimmune disease?

FMF is an autoinflammatory disease, which means the innate immune system is overactive and causes inflammation without a specific external trigger. Autoimmune diseases, in contrast, involve the adaptive immune system mistakenly attacking the body's own tissues, leading to a different range of conditions.

If I have FMF, will my children definitely inherit it?

FMF is inherited in an autosomal recessive pattern. This means your children would only inherit the condition if they received an altered *MEFV* gene from you AND an altered *MEFV* gene from your other parent. If your partner is not a carrier, your children would be carriers but typically not develop FMF.

References

  1. Özdoğan H, Ben-Chetrit E, Uğurlu S. 2nd Familial Mediterranean Fever Meeting. Clinical and experimental rheumatology. 2024. PMID: 39404483
  2. HELLER H, SOHAR E, SHERF L. Familial Mediterranean fever. A.M.A. archives of internal medicine. 1958. PMID: 13558745
  3. Bakir F, Martadha M. Familial Mediterranean fever. British medical journal (Clinical research ed.). 1981. PMID: 6781637
  4. Sarrabay G, Touitou I. Dominant familial Mediterranean fever. Rheumatology (Oxford, England). 2017. PMID: 27150192
  5. Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet (London, England). 1998. PMID: 9500348
  6. Muhn CY, Rosenthal D, Browne C. Familial Mediterranean fever. Archives of dermatology. 1998. PMID: 9722722
  7. Familial Mediterranean fever. British medical journal. 1980. PMID: 7407479
  8. Ben-Chetrit E, Nidorf M, Falk R. Inflammation, Colchicine, and Atherosclerotic Disease: Is Familial Mediterranean Fever an Exception That Proves the Rule? Journal of the American College of Cardiology. 2024. PMID: 38925725
Educational content. This page is not medical or genetic advice, is not individually reviewed by a clinician for each reader, and should not replace a consultation with a qualified healthcare professional or genetic counsellor.